NCT01240629View on ClinicalTrials.gov

Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 2, 2010

Primary Completion Date

February 2, 2017

Study Completion Date

February 2, 2017

Conditions
Prostate CancerHormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
Interventions
OTHER

laboratory biomarker analysis

Correlative study

OTHER

questionnaire administration

Correlative study

DRUG

doxorubicin-GnRH agonist conjugate AEZS-108

Given IV

Trial Locations (1)

90033-0804

University of Southern California, Los Angeles

Sponsors

Collaborators (1)

AEterna Zentaris
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

AEterna Zentaris

INDUSTRY

lead

University of Southern California

OTHER